News and Announcements

The 20th Anniversary PSC Partners Annual Conference took place in Phoenix, Arizona, on October 18-20, 2024. Throughout the conference...

Thanks to your active participation in the Registry, significant progress has been made in PSC research. Four publications using Registry...

A new survey is available in the Registry: the PSC Flare or Cholangitis Attack Patient Survey . Why take a survey about PSC...

A huge THANK YOU! to everyone who has kept the PSC Partners Patient Registry an active and constantly growing beacon of the patient voice...

Three Recent Announcements from: Pliant, NGM, and Chemomab PSC Partners is encouraged by the initial positive data from the CM-101 Phase...

On July 15, 2024, Pliant Therapeutics announced positive results from their Phase 2a INTEGRIS-PSC trial for bexotegrast in treatment of...

The repurposing of approved medications with potential new efficacy in rare diseases is challenging, as these medications are unlikely to...

The following is a message from Mirum Pharmaceuticals regarding their VISTAS study for volixibat, a possible new treatment for...

Dear Registry Participants (Current and Future),  This year is the 10th anniversary  of the PSC Partners Patient Registry, a perfect time...

Exciting news about the Pliant Therapeutics PSC clinical trial preliminary results from their global INTEGRIS-PSC Phase 2a trial for...

Health equity is the state in which everyone has a fair and just opportunity to attain their highest level of health*. The mission of PSC...

Issue 6 - June 2023 In this issue: From the Registry Director • New CZI Grant Awarded to PSC Partners • Patient Focus Groups Provide...

News from the EASLCongress 2023 meeting in Vienna From the "late-breaking" abstract session on June 24, 2023, results of the pre-planned...

Survey Results: Oral Vancomycin and Insurance Coverage PSC Partners received a request from patients to survey the PSC patient community...

Issue 5 - October 2022 Welcome! In this issue:  • From the Registry Director • The Clinical Trial Landscape in PSC • Current...

Statement From Gilead Sciences on September 27, 2022 Early Termination of Gilead-Sponsored Study GS-US-428-4194: A Phase 3, Randomized,...

In this issue: •  From the Registry Director • Mini-PFDDs • Patient Registry Video Tour • Help Us Grow & Diversify the Registry! • PSC...

Welcome! In this issue: • From the Registry Director • Profile: Dr. Frank Anania of the FDA • Your Registry Data at Work • PSC Partners...

Dear Registry Participant, Thank you for your participation in the PSC Partners Patient Registry. We are happy to bring the second issue...

A proof-of-concept Phase 2 trial conducted by Mayo Clinic and sponsored by Immunic has shown very early positive results. We hope that...